[1]李智恒,文青,蔡雪妮,等.IgA肾病治疗研究进展[J].新乡医学院学报,2023,40(3):295-300.[doi:10.7683/xxyxyxb.2023.03.019]
　LI Zhiheng,WEN Qing,CAI Xueni,et al.Research progress in the treatment of IgA nephropathy[J].Journal of Xinxiang Medical University,2023,40(3):295-300.[doi:10.7683/xxyxyxb.2023.03.019]
点击复制

IgA肾病治疗研究进展
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
40卷
期数:
2023年3期
页码:
295-300
栏目:
综述
出版日期:
2023-03-05

文章信息/Info

Title:
Research progress in the treatment of IgA nephropathy
作者:
李智恒; 文青; 蔡雪妮; 曾永秦; 严瑞
（贵州医科大学附属医院肾内科，贵州　贵阳　550004）
Author(s):
LI Zhiheng; WEN Qing; CAI Xueni; ZENG Yongqin; YAN Rui
(Department of Nephrology，the Affiliated Hospital of Guizhou Medical University,Guiyang 550004,Guizhou Province,China)
关键词:
IgA肾病; 支持治疗; 皮质类固醇; 免疫抑制; 靶向治疗; 分子生物疗法
Keywords:
IgA nephropathy; supportive care; corticosteroid; immunosuppression; targeted therapy; molecular biological therapy
分类号:
R69
DOI:
10.7683/xxyxyxb.2023.03.019
文献标志码:
A
摘要:
IgA肾病（IgAN）是成人常见的原发性肾小球疾病，约30%~40%的患者可能在20 a内进展为终末期肾病；由于对IgAN发病机制的了解不充分，目前其治疗仍以支持治疗为主。鉴于糖皮质激素、免疫抑制剂等传统药物疗效有限且存在一定不良反应，靶向治疗及分子生物疗法等已成为研究热点。本文就近年来关于IgAN的支持治疗、糖皮质激素和免疫抑制剂等传统药物治疗以及靶向治疗和分子生物治疗等新兴疗法的研究进展进行综述，以期为探索IgAN的管理和治疗提供新的思路与方向。
Abstract:
IgA nephropathy (IgAN ) is a common primary glomerular disease in adults,and about 30%-40% of patients may progress to end-stage renal disease within 20 years.Due to insufficient understanding of its pathogenesis,supportive care is still mainly treatment for IgAN at present.Given the limited efficacy and side effects of traditional medicines,such as glucocorticoids and immunosuppressant,targeted therapy and molecular biological therapy have becoming research hotspot.This article reviews the progress in supportive care,traditional medicines such as glucocorticoids and immunosuppressant,and new treatment strategy such as targeted therapy and molecular biological therapy of IgAN in recent years,so as to provide strategies and directions for exploring the management and treatment of IgAN.

参考文献/References:

［1］　LE W,LIANG S,HU Y,et al.Long-term renal survival and related risk factors in patients with IgA nephropathy:results from a cohort of 1 155 cases in a Chinese adult population［J］.Nephrol Dial Transplant,2012,27(4):1479-1485.
［2］　RODRIGUES J C,HAAS M,REICH H N.IgA nephropathy［J］.Clin J Am Soc Nephrol,2017,12(4):677-686.
［3］　杜夕雯,肖敦明,敖超群,等.中国IgA肾病成人疾病负担［J］.中国药物经济学,2022,17(7):46-52.
DU X W,XIAO D M,AO C Q,et al.Disease burden of IgA nephropathy in China［J］.Chin J Pharm Econ,2022,17(7):46-52.
［4］　NOVAK J,BARRATT J,JULIAN B A,et al.Aberrant glycosylation of the IgA1 molecule in IgA nephropathy［J］.Semin Nephrol,2018,38(5):461-476.
［5］　WU M Y,CHEN Y C,CHIU I J,et al.Genetic insight into primary glomerulonephritis［J］.Nephrology (Carlton),2022,27(8):649-657.
［6］　HUANG X,XU G.An update on targeted treatment of IgA nephropathy:an autoimmune perspective［J］.Front Pharmacol,2021,12:715253.
［7］　KIDNEY DISEASE:IMPROVING GLOBAL OUTCOMES (KDIGO) GLOMERULAR DISEASES WORK GROUP.KDIGO 2021 clinical practice guideline for the management of glomerular diseases［J］.Kidney Int,2021,100(4S):S1-S276.
［8］　ZHAO Y,FAN H,BAO B Y.Efficacy and safety of renin-angiotensin aldosterone system inhibitor in patients with IgA nephropathy:a meta-analysis of randomized controlled trials［J］.Iran J Public Health,2019,48(9):1577-1588.
［9］　HUO Z,YE H,YE P,et al.Comparative efficacy of different renin angiotensin system blockade therapies in patients with IgA nephropathy:a Bayesian network meta-analysis of 17 RCTs［J］.Peer J,2021,9:e11661.
［10］　KONISHI Y,OKADA N,OKAMURA M,et al.Sodium sensitivity of blood pressure appearing before hypertension and related to histological damage in immunoglobulin a nephropathy［J］.Hypertension,2001,38(1):81-85.
［11］　FILIPPINI T,MALAVOLTI M,WHELTON P K,et al.Sodium intake and risk of hypertension:a systematic review and dose-response meta-analysis of observational cohort studies［J］.Curr Hypertens Rep,2022,24(5):133-144.
［12］　FILIPPINI T,MALAVOLTI M,WHELTON P K,et al.Blood pressure effects of sodium reduction:dose-response meta-analysis of experimental studies［J］.Circulation,2021,143(16):1542-1567.
［13］　YUE H,ZHOU P,XU Z,et al.Effect of low-protein diet on kidney function and nutrition in nephropathy:a systematic review and meta-analysis of randomized controlled trials［J］.Clin Nutr,2020,39(9):2675-2685.
［14］　HAHN D,HODSON E M,FOUQUE D.Low protein diets for non-diabetic adults with chronic kidney disease［J］.Cochrane Database Syst Rev,2020,10(10):CD001892.
［15］　KOULOURIDIS E,KOULOURIDIS I.Is the dietary protein restriction achievable in chronic kidney disease? The impact upon quality of life and the dialysis delay［J］.Hippokratia,2011,15 (Suppl 1):3-7.
［16］　WANG S,QIN A,PEI G,et al.Cigarette smoking may accelerate the progression of IgA nephropathy［J］.BMC Nephrol,2021,22(1):239.
［17］　WANG Q,ZHANG J J,DOU W J,et al.Impact of body mass index on primary immunoglobulin A nephropathy prognosis:a systematic review and meta-analysis［J］.Int Urol Nephrol,2022,54(5):1067-1078.
［18］　HIRAHASHI J.Omega-3 polyunsaturated fatty acids for the treatment of IgA nephropathy［J］.J Clin Med,2017,6(7):70.
［19］　MORIYAMA T,KUMON S,KAMIYAMA T,et al.The renoprotective effects of docosahexaenoic acid as an add-on therapy in patients receiving eicosapentaenoic acid as treatment for IgA nephropathy:a pilot uncontrolled trial［J］.Int Med,2018,57(2):173-179.
［20］　ALEXOPOULOS E,STANGOU M,PANTZAKI A,et al.Treatment of severe IgA nephropathy with omega-3 fatty acids:the effect of a "very low dose" regimen［J］.Ren Fail,2004,26(4):453-459.
［21］　UWAEZUOKE S N,MUONEKE U V,MBANEFO N R.The supportive treatment of IgA nephropathy and idiopathic nephrotic syndrome:how useful are omega-3 polyunsaturated fatty acids?［J］.Int J Nephrol Renovasc Dis,2020,13:27-35.
［22］　LI Y,WAN Q,LAN Z,et al.Efficacy and indications of tonsillectomy in patients with IgA nephropathy:a retrospective study［J］.PeerJ,2022,10:e14481.
［23］　NAKATA J,SUZUKI Y,SUZUKI H,et al.Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy［J］.PLoS One,2014,9(2):e89707.
［24］　DUAN J,LIU D,DUAN G,et al.Long-term efficacy of tonsillectomy as a treatment in patients with IgA nephropathy:a meta-analysis［J］.Int Urol Nephrol,2017,49(1):103-112.
［25］　LIU L L,WANG L N,JIANG Y,et al.Tonsillectomy for IgA nephropathy:a meta-analysis［J］.Am J Kidney Dis,2015,65(1):80-87.
［26］　PEI G,TAN J,TANG Y,et al.Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria［J］.Medicine(Baltimore),2020,99(24):e20513.
［27］　RAUEN T,EITNER F,FITZNER C,et al.Intensive supportive care plus immunosuppression in IgA nephropathy［J］.N Engl J Med,2015,373(23):2225-2236.
［28］　RAUEN T,WIED S,FITZNER C,et al.After ten years of follow-up,no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy［J］.Kidney Int,2020,98(4):1044-1052.
［29］　LV J,ZHANG H,WONG M G,et al.Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy:the TESTING randomized clinical trial［J］.JAMA,2017,318(5):432-442.
［30］　LV J,WONG M G,HLADUNEWICH M A,et al.Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy:the TESTING randomized clinical trial［J］.JAMA,2022,327(19):1888-1898.
［31］　TRIMARCHI H,BARRATT J,CATTRAN D C,et al.Oxford classification of IgA nephropathy 2016:an update from the IgA Nephropathy Classification Working Group［J］.Kidney Int,2017,91(5):1014-1021.
［32］　BECK N,WALZ G,SCHNEIDER J.Effect of cyclophosphamide and glucocorticoid therapy in IgA nephropathy:a single-center retrospective analysis［J］.Kidney,2022,3(3):506-515.
［33］　TUMLIN J A,LOHAVICHAN V,HENNIGAR R.Crescentic,proliferative IgA nephropathy:clinical and histological response to methylprednisolone and intravenous cyclophosphamide［J］.Nephrol Dial Transplant,2003,18(7):1321-1329.
［34］　DU B,JIA Y,ZHOU W,et al.Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy:an update meta-analysis［J］.BMC Nephrol,2017,18(1):245.
［35］　ZHENG J,GONG X,WU Z.Immunosuppressive agents in the treatment of IgA nephropathy:a meta-analysis of clinical randomized controlled literature［J］.Niger J Clin Pract,2020,23(4):437-449.
［36］　LIU T,WANG Y,MAO H,et al.Efficacy and safety of immunosuppressive therapies in the treatment of high-risk IgA nephropathy:a network meta-analysis［J］.Medicine (Baltimore),2021,100(8):e24541.
［37］　JIA Q,MA F,ZHAO J,et al.Effect of corticosteroids combined with cyclophosphamide or mycophenolate mofetil therapy for IgA nephropathy with stage 3 or 4 chronic kidney disease:a retrospective cohort study［J］.Front Pharmacol,2022,13:946165.
［38］　ZHANG Q,SHI S F,ZHU L,et al.Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy［J］.Am J Nephrol,2012,35(4):312-320.
［39］　TAN J,DONG L,YE D,et al.The efficacy and safety of immunosuppressive therapies in the treatment of IgA nephropathy:a network meta-analysis［J］.Sci Rep,2020,10(1):6062.
［40］　YAN Z,WANG J,HUANG T,et al.Effectiveness and safety of tacrolimus treatment for IgA nephropathy:a prospective cohort study［J］.Med Clin (Barc),2022,158(12):596-602.
［41］　LV J,YANG Y,ZHANG H,et al.Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study［J］.J Am Soc Nephrol,2013,24(12):2118-2125.
［42］　王梓,张军军,左力,等.血浆置换治疗新月体型IgA肾病的有效性分析:多中心队列研究［J］.北京大学学报(医学版),2022,54(5):1038-1046.
WANG Z,ZHANG J J,ZUO L,et al.Efficacy of plasma exchange in severe crescentic IgA nephropathy:a multicentered,cohort study［J］.J Peking Univ(Health Sci),2022,54(5):1038-1046.
［43］　FELLSTRM B C,BARRATT J,COOK H,et al.Targeted-release budesonide versus placebo in patients with IgA nephropathy(NEFIGAN):a double-blind,randomized,placebo-controlled phase 2b trial［J］.Lancet,2017,389(10084):2117-2127.
［44］　LUNDBERG S,WESTERGREN E,SMOLANDER J,et al.B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis［J］.Clin Kidney J,2017,10(1):20-26.
［45］　LAFAYETTE R A,CANETTA P A,ROVIN B H,et al.A randomized,controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction［J］.J Am Soc Nephrol,2017,28(4):1306-1313.
［46］　GAO R,WU W,WEN Y,et al.Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy［J］.Int Urol Nephrol,2017,49(7):1233-1241.
［47］　LIU L J,YANG Y Z,SHI S F,et al.Effects of hydroxychloroquine on proteinuria in IgA nephropathy:a randomized controlled trial［J］.Am J Kidney Dis,2019,74(1):15-22.
［48］　YANG Y Z,CHEN P,LIU L J,et al.Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy:a case-control study［J］.BMC Nephrol,2019,20(1):297.
［49］　STEFAN G,MIRCESCU G.Hydroxychloroquine in IgA nephropathy:a systematic review［J］.Ren Fail,2021,43(1):1520-1527.
［50］　秦剑,熊加川,赵景宏.RAASi基础上羟氯喹对比螺内酯治疗IgA肾病的疗效和安全性分析［J］.陆军军医大学学报,2022,44(13):1362-1369.
QIN J,XIONG J C,ZHAO J H.Efficacy and safety of HCQ versus spironolactone in treatment of IgA nephropathy based on RAASi:a real-world study［J］.J Army Med Univ,2022,44(13):1362-1369.
［51］　陶承蓉,王墨.IgA肾病靶向治疗研究进展［J］.儿科药学杂志,2022,28(2):52-55.
TAO C R,WANG M.Progress of targeted therapy for IgA nephropathy［J］.J Pediatr Pharm,2022,28(2):52-55.
［52］　丁晓欢,吕静,张天舒,等.中药治疗IgA肾病临床疗效的meta分析［J］.中国处方药,2020,18(9):153-156.
DING X H,LYU J,ZHANG T S,et al.A meta-analysis of the clinical efficacy of Chinese medicine in the treatment of IgA nephropathy［J］.J China Prescript Drug,2020,18(9):153-156.
［53］　卢登勇,石晓冬,陈宇珊,等.中医药治疗免疫球蛋白A肾病系统评价/Meta分析的再评价［J］.中医临床研究,2022,14(11):135-138.
LU D Y,SHI X D,CHEN Y S,et al.Re-evaluation of system evaluation/meta-analysis of TCM treatment of IgA nephropathy［J］.Clin J Chin Med,2022,14(11):135-138.
［54］　常美莹,赵明明,余怡,等.雷公藤多苷片联合ACEI/ARB治疗IgA肾病蛋白尿的回顾性研究［J］.世界中西医结合杂志,2022,17(10):2035-2038,2043.
CHANG M Y,ZHAO M M,YU Y,et al.A retrospective study of tripterygium wilfordii polyglycoside tablets combined with ACEI/ARB in the treatment of proteinuria in IgA nephropathy［J］.World J Integr Trad West Med,2022,17(10):2035-2038,2043.

相似文献/References:

[1]史洋洋,毕凌云,杨达胜.儿童紫癜性肾炎和IgA肾病的发病机制及病理分型研究进展[J].新乡医学院学报,2021,38(4):386.[doi:10.7683/xxyxyxb.2021.04.020]
[2]马媛媛,姬　萌,郭醉爽,等.昆仙胶囊治疗原发性IgA肾病疗效观察[J].新乡医学院学报,2021,38(10):961.[doi:10.7683/xxyxyxb.2021.10.013]
　MA Yuanyuan,JI Meng,GUO Zuishuang,et al.Effect of Kunxian capsule in the treatment of primary IgA nephropathy[J].Journal of Xinxiang Medical University,2021,38(3):961.[doi:10.7683/xxyxyxb.2021.10.013]
[3]姚俊东,刘彬彬,王运昌,等.超微血流成像联合声脉冲辐射力弹性成像对IgA肾病的诊断价值[J].新乡医学院学报,2022,39(7):637.[doi:10.7683/xxyxyxb.2022.07.008]
　YAO Jundong,LIU Binbin,WANG Yunchang,et al.Value of superb microvascular imaging combined with aoustic radiation force impulse in diagnosis of IgA nephropathy[J].Journal of Xinxiang Medical University,2022,39(3):637.[doi:10.7683/xxyxyxb.2022.07.008]
[4]孙晓莉,郭永兵.小剂量泼尼松联合他克莫司治疗老年IgA肾病疗效观察[J].新乡医学院学报,2022,39(8):756.[doi:10.7683/xxyxyxb.2022.08.011]
　SUN Xiaoli,GUO Yongbing.Effect of low-dose prednisone combined with tacrolimus in the treatment of elderly patients with IgA nephropathy[J].Journal of Xinxiang Medical University,2022,39(3):756.[doi:10.7683/xxyxyxb.2022.08.011]

更新日期/Last Update: 2023-03-05